{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "esgPopulated": false, "market": "dr_market", "longName": "Alpine Immune Sciences, Inc.", "marketState": "REGULAR", "regularMarketPrice": 7.05, "messageBoardId": "finmb_283828497", "exchange": "FRA", "shortName": "ALPINE IMMUNE SCI.DL-,001", "exchangeTimezoneShortName": "CEST", "exchangeTimezoneName": "Europe/Berlin", "regularMarketChangePercent": -0.7042213, "gmtOffSetMilliseconds": 7200000, "fiftyTwoWeekLowChange": 1.645, "fiftyTwoWeekLowChangePercent": 0.3043478, "fiftyTwoWeekRange": "5.405 - 9.05", "fiftyTwoWeekHighChange": -2.0, "fiftyTwoWeekHighChangePercent": -0.22099447, "fiftyTwoWeekLow": 5.405, "fiftyTwoWeekHigh": 9.05, "earningsTimestamp": 1683836100, "earningsTimestampStart": 1691578740, "earningsTimestampEnd": 1692014400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.71, "epsForward": -1.53, "epsCurrentYear": -1.34, "firstTradeDateMilliseconds": 1436508000000, "priceHint": 2, "regularMarketChange": -0.049999714, "regularMarketTime": 1683875702, "regularMarketDayHigh": 7.05, "regularMarketDayRange": "7.05 - 7.05", "regularMarketDayLow": 7.05, "regularMarketVolume": 20, "regularMarketPreviousClose": 7.1, "bid": 7.05, "ask": 7.3, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 7.05, "averageDailyVolume3Month": 4, "averageDailyVolume10Day": 0, "priceEpsCurrentYear": -5.261194, "sharesOutstanding": 47965800, "bookValue": 3.902, "fiftyDayAverage": 6.9309, "fiftyDayAverageChange": 0.119100094, "fiftyDayAverageChangePercent": 0.01718393, "twoHundredDayAverage": 6.97765, "twoHundredDayAverageChange": 0.072350025, "twoHundredDayAverageChangePercent": 0.010368824, "marketCap": 338393664, "forwardPE": -4.6078434, "priceToBook": 1.8067658, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.6 - Buy", "tradeable": false, "cryptoTradeable": false, "symbol": "34LA.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "188 East Blaine Street", "address2": "Suite 200", "city": "Seattle", "state": "WA", "zip": "98102", "country": "United States", "phone": "206 788 4545", "website": "https://www.alpineimmunesciences.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mitchell H. Gold M.D.", "age": 54, "title": "Exec. Chairman & CEO", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 778200, "fmt": "778.2k", "longFmt": "778,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3826649, "fmt": "3.83M", "longFmt": "3,826,649"}}, {"maxAge": 1, "name": "Dr. Stanford  Peng M.D., Ph.D.", "age": 51, "title": "Pres and Head of R&D", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 751200, "fmt": "751.2k", "longFmt": "751,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1979010, "fmt": "1.98M", "longFmt": "1,979,010"}}, {"maxAge": 1, "name": "Mr. Paul  Rickey", "age": 43, "title": "Sr. VP, CFO, Treasurer & Sec.", "yearBorn": 1979, "fiscalYear": 2022, "totalPay": {"raw": 577100, "fmt": "577.1k", "longFmt": "577,100"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 540467, "fmt": "540.47k", "longFmt": "540,467"}}, {"maxAge": 1, "name": "Dr. Wayne R. Gombotz", "age": 63, "title": "Chief Technology Officer", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Temre  Johnson", "title": "Head of IR & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Remy  Durand Ph.D.", "age": 37, "title": "Chief Bus. Officer", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Pamela  Holland Ph.D.", "title": "Sr. VP of Research", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Andrew Seth Sandler M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}